The global valganciclovir market is projected to reach USD 342.8 million in 2025, driven by the increasing prevalence of cytomegalovirus (CMV) infections among immunocompromised patients. As the demand for effective antiviral treatments rises, market growth is expected to continue, with sales anticipated to reach USD 498.80 million by 2033. With a Compound Annual Growth Rate (CAGR) of 4.80% from 2025 to 2033, the market is set for steady expansion. Key factors fueling this growth include advancements in antiviral drug formulations, rising organ transplant procedures, and increasing awareness of CMV-related complications in patients with weakened immune systems.